Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-29
2008-01-29
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S549000
Reexamination Certificate
active
07323476
ABSTRACT:
The present invention relates to the use of certain novel myriceric acid derivatives of the formula:which are inhibitors of nuclear factor kappa B (NF-κB) and inhibit the activity of the endothelin receptor for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-κB inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.
REFERENCES:
patent: 5220930 (1993-06-01), Gentry
patent: 5248807 (1993-09-01), Fujimoto et al.
patent: 5320131 (1994-06-01), Dull
patent: 5463107 (1995-10-01), Konoike et al.
patent: 5587505 (1996-12-01), Konoike et al.
patent: 5944026 (1999-08-01), Kopsch et al.
patent: 6615843 (2003-09-01), Pera
patent: 6766803 (2004-07-01), An
patent: 2005/0165087 (2005-07-01), Callahan et al.
Cecil Textbook of Medicine, 21st Edition, vol. 1, Goldman et al., (Eds), published 2000 by W.B. Saunders, (PA), pp. 1060-1074.
Bremner, Paul and Michael Heinrich, Natural Products as Targeted Modulators of the Nuclear Factor-kB Pathway, Journal of Pharmacy and Pharmacology, 2002, 54: 453-472, JPP, London UK.
McNulty, Susan E., Raul Del Rosario, Dazhi Cen, Frank L. Meyskens Jr. and Sun Yang, Comparative Expression of Normal Skin vs. Benign Intradermal Naevus and Human Metastatic Melanoma Biopsies, Pigment Cell Research, Apr. 2004, p. 173, vol. 17 Issue 2.
Sakurawi, Kensuke, Fumio Yasuda, Takehiko Tozyo, Miharu Nakamura, Tomohiro Sato, Junko Kikuchi, Yoshihiro Terui, Yuji Ikenishi, Tsuyoshi Iwata, Kazuhiro Takahashi, Toshiro Konoike, Shin-Ichi Mihara, and Masafumi Fujimoto, Endothelin Receptor Antagonist Triterpenoid, Myriceric Acid A, Isolated fromMyrica cerifera, and Structure Activity Relationship of Its Derivatives, Chem. Pharm. Bull., Feb. 1996, 44(2) 343-351, Pharmaceutical Society of Japan.
Mihara, Shin-Ichi, Fumiyo Tozawa Kohji Itazaki, and Masafumi Fujimoto, Binding Characterization of [3H]S-0139, and Antagonist of the Endothelin ETA Receptor Subtype, European Journal of Pharmacology, 1998, 342 (1998) 319-324, Elsevier Science B.V.
Benigni, Ariela, Norberto Perico, and Giuseppe Remuzzi, The Potential of Endothelin Antagonism as a Therapeutic Approach, Monthly Focus: Cardiovascular & Renal, 2004, 13(11):1419-1435, Ashley Publications Ltd.
Mihara, Shin-Ichi, Shigeyuki Nakajima, Shoichi Matumura, Toshiro Kohnokike, and Masafumi Fujimoto, Pharmacological Characterization of a Potent Nonpeptide Endothelin Receptor Antagonist, 97-139, The Journal of Pharmacology and Experimental Therapeutics, 1994, 1122-1128, vol. 268, No. 3, The American Society for Pharmacology and Experimental Therapeutics, USA.
McKay, Lorraine I. and John A. Cidlowski, Molecular Control of Immune/Inflammatory Responses: Interactions Between Nuclear Factor-kB and Steroid Receptor-Signaling Pathways, Endocrine Reviews, 1999, 20(4): 435-459, The Endocrine Society.
Dinkova-Kostova, Albena T., Karen T. Liby, Katherine K. Stephenson, W. David Holtzclaw, Ziangqun Gao, Nanjoo Suh, Charlotte Williams, Renee Risingsong, Tadashi Honda, Gordon W. Gribble, Michael B. Sporn, and Paul Talalay, Extremely Potent Triterpenoid Inducers of the Phase 2 Response: Correlations of Protection Against Oxidant and Inflammatory Stress, Medical Sciences, Mar. 22, 2005, 4584-4589, vol. 102, No. 12, The National Academy of Sciences of the USA.
Dev Inderjit Kumar
Subbiah Ven
Henley III Raymond J.
Passé James G.
Passé Intellectual Property, LLC
SaviPu Pharmaceuticals
LandOfFree
Myriceric acid derivatives for the treatment of cancer,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Myriceric acid derivatives for the treatment of cancer,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Myriceric acid derivatives for the treatment of cancer,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747390